PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112259 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Qifeng Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Basic Medicine College, Anhui Medical University, Hefei, 230032, China; Key Laboratory of Anti-inflammatory and Immunopha…. Hauptthemen laut MEDLINE: Hippocampus, Interleukin-1beta, Neurons, NFATC Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Province Department of Education, Anhui Provincial Natural Science Foundation.
Abstract (Originalsprache)
Alzheimer's disease (AD) is a progressive neurodegenerative disease. Neuronal calcium overload plays an important role in Aβ deposition and neuroinflammation, which are strongly associated with AD. However, the specific mechanisms by which calcium overload contributes to neuroinflammation and AD and the relationship between them have not been elucidated. Phospholipase C (PLC) is involved in regulation of calcium homeostasis, and CN-NFAT1 signaling is dependent on intracellular Ca2+ ([Ca2+]i) to regulate transcription of genes. Therefore, we hypothesized that the PLC-CN-NFAT1 signaling might mediate the interaction between Aβ and inflammation to promote neuronal injury in AD. In this experiment, the results showed that the levels of Aβ, IL-1β and [Ca2+]i in the hippocampal primary neurons of APP/PS1 mice (APP neurons) were significantly increased. IL-1β exposure also significantly increased Aβ and [Ca2+]i in HT22 cells, suggesting a close association between Aβ and IL-1β in the development of AD. Furthermore, PLC activation induced significant calcium homeostasis imbalance, cell apoptosis, Aβ and ROS production, and significantly increased expressions of CN and NFAT1, while PLC inhibitor significantly reversed these changes in APP neurons and IL-1β-induced HT22 cells. Further results indicated that PLC activation significantly increased the expressions of NOX2, APP, BACE1, and NCSTN, which were inhibited by PLC inhibitor in APP neurons and IL-1β-induced HT22 cells. All indications point to a synergistic interaction between Aβ and IL-1β by activating the PLC-CN-NFAT1 signal, ultimately causing a vicious cycle, resulting in neuronal damage in AD. The study may provide a new idea and target for treatment of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Basic Medicine College, Anhui Medical University, Hefei, 230032, China; Key Laboratory of Anti-inflammatory and Immunopharmacology, Ministry of Education, Anhui Medical University, Hefei, 230…
- Department of Pharmacy, the First Affiliated Hospital of Anhui Medical University, Hefei 230032, Anhui, China.
Förderung
- National Natural Science Foundation of China
- Anhui Province Department of Education
- Anhui Provincial Natural Science Foundation
Zitieren
APA
Shi, Q., Sun, X., Zhang, H., Yang, L., Fu, Y., Wang, G., Su, Y., Li, W., & Li, W. (2024). PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112259
Vancouver
Shi Q, Sun X, Zhang H, Yang L, Fu Y, Wang G, et al. PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112259
BibTeX
@article{Shi2024,
author = {Shi, Qifeng and Sun, Xiangyu and Zhang, Hui and Yang, Liu and Fu, Yinglin and Wang, Guohang and Su, Yong and Li, Weiping and Li, Weizu},
title = {PLC-CN-NFAT1 signaling-mediated Aβ and IL-1β crosstalk synergistically promotes hippocampal neuronal damage},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112259}
}
EUVIMED